Muscle Spasticity Market, by Drug Type (Baclofen, Botulinum Toxin, Diazepam, Tizanidine, Dantrolene Sodium, and Others), by Route of Administration (Oral, Intramuscular, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Dec 2021

Code : CMI4827

Pages :192

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

Lack of availability of skilled professionals
Overall high cost of treatment
Inadequate reimbursement
Lack of disease awareness in emerging economies

Global Muscle Spasticity Market: Restraint

The major factors that hinder the growth of the global muscle spasticity market include lack of availability of skilled professionals, overall high cost of treatment, inadequate reimbursement, and lack of disease awareness in emerging economies.

Growth Drivers:

Increasing global healthcare expenditure
Launch of novel therapeutics
Advancements in the health care industry

Global Muscle Spasticity Market– Impact of Coronavirus (COVID-19) Pandemic

COVID-19 has considerably impacted the muscle spasticity market. Most of the activities involved in the treatment of muscle spasticity have been either postponed or suspended. This prolonged suspension of activities has potentially exposed a lot of patients to the consequences of untreated spasticity.

COVID-19 has caused home confinement of patients, which may have triggered spasticity. For instance, according to an article published in ‘BioMed Research International journal’ on October 2021, both the number and the duration of oscillations (right leg), as well as the first swing excursion and relaxation index (left leg), decreased after home confinement, indicating increased spasticity.

Moreover, spasticity is a multifactorial problem, which is also influenced by psychological and behavioral aspects. COVID-19 has impacted the behavioral and psychological health of individuals (e.g., anxiety, fear of infection, and poorer sleep quality), which may have contributed to increased spasticity in people with multiple sclerosis.